Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Tela Bio (TELA) to $1.25 from $2 and keeps a Neutral rating on the shares. The firm notes the company reported Q3 results which missed its estimate on the top-line and on the operating loss side of things. Revenue guidance for the year was lowered, which is certainly a disappointing update, Piper adds.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TELA: